180 related articles for article (PubMed ID: 22527932)
1. Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue.
Mohammad MA; Zeeneldin AA; Abd Elmageed ZY; Khalil EH; Mahdy SM; Sharada HM; Sharawy SK; Abdel-Wahab AH
Mol Cell Biochem; 2012 Jul; 366(1-2):269-75. PubMed ID: 22527932
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma.
Mylona E; Nomikos A; Magkou C; Kamberou M; Papassideri I; Keramopoulos A; Nakopoulou L
Histopathology; 2007 Feb; 50(3):338-47. PubMed ID: 17257129
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
4. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer.
Dalberg K; Eriksson E; Enberg U; Kjellman M; Bäckdahl M
World J Surg; 2000 Mar; 24(3):334-40. PubMed ID: 10658069
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of membrane type 1 and 2 matrix metalloproteinase expression and gelatinase A activity in bladder cancer.
Mohammad MA; Ismael NR; Shaarawy SM; El-Merzabani MM
Int J Biol Markers; 2010; 25(2):69-74. PubMed ID: 20586027
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
[TBL] [Abstract][Full Text] [Related]
7. Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer.
Zeeneldin AA; Mohamed AM; Abdel HA; Taha FM; Goda IA; Abodeef WT
Indian J Cancer; 2009; 46(1):54-60. PubMed ID: 19282568
[TBL] [Abstract][Full Text] [Related]
8. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Sivula A; Talvensaari-Mattila A; Lundin J; Joensuu H; Haglund C; Ristimäki A; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2005 Feb; 89(3):215-20. PubMed ID: 15754118
[TBL] [Abstract][Full Text] [Related]
9. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
Jones JL; Glynn P; Walker RA
J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
[TBL] [Abstract][Full Text] [Related]
10. Increased serum level of membrane type 1-matrix metalloproteinase (MT1-MMP/MMP-14) in patients with breast cancer.
Laudański P; Swiatecka J; Kozłowski L; Leśniewska M; Wojtukiewicz M; Wołczyński S
Folia Histochem Cytobiol; 2010 Jan; 48(1):101-3. PubMed ID: 20529824
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma.
Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Br J Cancer; 2003 Oct; 89(7):1270-5. PubMed ID: 14520459
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients.
Puzovic V; Brcic I; Ranogajec I; Jakic-Razumovic J
Neoplasma; 2014; 61(4):439-46. PubMed ID: 24645837
[TBL] [Abstract][Full Text] [Related]
14. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma.
Ip YC; Cheung ST; Fan ST
Mol Carcinog; 2007 Mar; 46(3):225-30. PubMed ID: 17219425
[TBL] [Abstract][Full Text] [Related]
15. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases -2 and -9 in lymph node-negative untreated breast cancer patients.
Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
J BUON; 2013; 18(4):866-73. PubMed ID: 24344010
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.
Ranogajec I; Jakić-Razumović J; Puzović V; Gabrilovac J
Med Oncol; 2012 Jun; 29(2):561-9. PubMed ID: 21611838
[TBL] [Abstract][Full Text] [Related]
18. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients.
Ranuncolo SM; Armanasco E; Cresta C; Bal De Kier Joffe E; Puricelli L
Int J Cancer; 2003 Sep; 106(5):745-51. PubMed ID: 12866035
[TBL] [Abstract][Full Text] [Related]
19. Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer.
Zhang M; Teng XD; Guo XX; Li ZG; Han JG; Yao L
Breast; 2013 Jun; 22(3):330-4. PubMed ID: 22995648
[TBL] [Abstract][Full Text] [Related]
20. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma.
Gilles C; Polette M; Seiki M; Birembaut P; Thompson EW
Lab Invest; 1997 May; 76(5):651-60. PubMed ID: 9166284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
